Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects

Since sodium stibogluconate (SSG) inhibited phosphatases including SHP-1 and augmented anti-tumor actions of IFN-α2b in vitro and in mice, two Phase I trials of SSG/IFN-α2b combination were undertaken to evaluate safety and target inhibition. Escalating doses of SSG (200-1200 mg/m(2)) and fixed dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Taolin, Elson, Paul, Mitsuhashi, Masato, Jacobs, Barbara, Hollovary, Emese, Budd, G. Thomas, Spiro, Timothy, Triozzi, Pierre, Borden, Ernest C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282074/
https://www.ncbi.nlm.nih.gov/pubmed/22201704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282074/
https://www.ncbi.nlm.nih.gov/pubmed/22201704

Ejemplares similares